Chardan Capital lowered shares of Vascular Biogenics (NASDAQ:VBLT) from a buy rating to a neutral rating in a research report report published on Thursday, Marketbeat.com reports. The firm currently has $3.00 target price on the biopharmaceutical company’s stock, down from their previous target price of $25.00.
VBLT has been the subject of several other research reports. Zacks Investment Research downgraded Vascular Biogenics from a hold rating to a sell rating in a research note on Thursday, January 25th. HC Wainwright downgraded Vascular Biogenics from a buy rating to a neutral rating and set a $3.00 price objective for the company. in a research report on Thursday. ValuEngine upgraded Vascular Biogenics from a sell rating to a hold rating in a research report on Friday, February 2nd. Piper Jaffray Companies downgraded Vascular Biogenics from an overweight rating to a neutral rating and set a $4.00 price objective for the company. in a research report on Thursday. Finally, JMP Securities downgraded Vascular Biogenics from an outperform rating to a market perform rating in a research report on Thursday. Two research analysts have rated the stock with a sell rating and four have assigned a hold rating to the company. The company currently has an average rating of Hold and a consensus price target of $3.33.
Shares of Vascular Biogenics (NASDAQ VBLT) opened at $2.60 on Thursday. Vascular Biogenics has a 52 week low of $2.30 and a 52 week high of $9.05. The firm has a market capitalization of $77.28, a P/E ratio of -3.29 and a beta of -2.44.
Vascular Biogenics Company Profile
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.
Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.